Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cyproheptadine→

Cyproheptadine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
129-03-3
Molecular formula
C21H21N
Molecular weight
287.3981 g/mol
Drug class
First-generation antihistamineH1 and serotonin 5-HT2 receptor antagonist
Mechanism of action
Antagonises histamine H1 receptors and serotonin 5-HT2 receptors, with additional anticholinergic activity. This reduces allergic symptoms and can influence appetite and serotonergic signalling.
Indications / reported uses
  • Symptomatic relief of allergic rhinitis, urticaria and pruritus in authorised products
  • Treatment of selected serotonin-mediated conditions such as serotonin syndrome is off-label and specialist-directed; appetite stimulation is not a universal approved indication

Sources: US DailyMed — Cyproheptadine hydrochloride · NLM MeSH — Cyproheptadine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cyproheptadine Environmental Risk Assessment (ERA) (the Cyproheptadine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.